Company intelligence / Profile preview

ToLymph

Richmond Hill, Ontario, Canadapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

ToLymph is developing SMS001, a novel form of paclitaxel targeting tubulin, as an adjuvant therapy to control tumor recurrence in stage Ib–IIIa non-small cell lung cancer. The company is currently sponsoring a Phase IIa clinical trial evaluating the safety and therapeutic effect of SMS001 in this patient population. Historical data also indicate activity or development in pancreatic adenocarcinoma metastatic and acinar cell carcinoma.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on ToLymph.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ToLymph.

Explore the full profile